Ubs Asset Management Americas Inc Cel Sci Corp Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $83,643 - $161,775	-32,420 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $45,891 - $145,339	-5,287 Reduced 14.02%	32,420 $281,000
Q1 2021 May 14, 2021	BUY	$12.0 - $27.64 $52,800 - $121,616	4,400 Added 13.21%	37,707 $573,000
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $2,338 - $2,908	200 Added 0.6%	33,307 $424,000
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $322,793 - $582,683	33,107 New	33,107 $493,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $27.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.